Maryland Attorney General Anthony G. Brown has joined a coalition of 48 states and territories in a $29.6 million settlement with generic drug manufacturer Glenmark.
The settlement resolves allegations that Glenmark participated in a long-running conspiracy to inflate and manipulate prices, reduce competition and restrain trade involving numerous generic prescription drugs.
Maryland will receive $178,000 from the settlement.
Under the agreement, Glenmark will cooperate with ongoing multistate litigation involving 33 corporate defendants and 25 individual executives. The company must also maintain an antitrust compliance program for at least seven years, report potential violations to attorneys general and implement internal reforms intended to support competition and compliance with antitrust laws.
The Glenmark agreement follows settlements with Lannett, Bausch, Apotex and Heritage totaling $66.95 million. The states are preparing for the first trial in the litigation, which will be held in Hartford, Connecticut, and is expected to be scheduled for early 2027.
Consumers who purchased generic prescription drugs manufactured by Glenmark, Lannett, Bausch, Apotex or Heritage between May 2009 and December 2019 may be eligible for compensation.
Eligibility information is available by calling 1-866-290-0182, emailing info@AGGenericDrugs.com or visiting www.AGGenericDrugs.com.
The Maryland Office of the Attorney General has participated in the multistate antitrust cases since 2016. Three complaints have been filed involving generic drug manufacturers, executives and numerous prescription drugs.
The investigations include evidence from cooperating witnesses, more than 20 million documents and millions of phone records involving more than 600 sales and pricing employees in the generic drug industry.
The coalition involved in the Glenmark settlement includes Maryland, Pennsylvania, Virginia, West Virginia, the District of Columbia and 43 other states and territories.
